Story perspectives

FDA Rejects uniQure's AMT-130 for Huntington's Approval

3/3/2026

Summary

Story summary

The U.S. Food and Drug Administration rejected uniQure's data for AMT-130, finding insufficient evidence for Huntington's disease approval.
The FDA recommended a Phase 3 trial with a randomized, double-blind, sham-controlled design, potentially delaying AMT-130's market entry.
UniQure plans to engage with the FDA to discuss study designs and is considering updates to its Phase 1/2 analysis.
The decision raises concerns about regulatory flexibility for rare-disease therapies, as many in the Huntington's community had hoped for expedited approval.

1 of 1

Story summary

The U.S. Food and Drug Administration rejected uniQure's data for AMT-130, finding insufficient evidence for Huntington's disease approval.
The FDA recommended a Phase 3 trial with a randomized, double-blind, sham-controlled design, potentially delaying AMT-130's market entry.
UniQure plans to engage with the FDA to discuss study designs and is considering updates to its Phase 1/2 analysis.
The decision raises concerns about regulatory flexibility for rare-disease therapies, as many in the Huntington's community had hoped for expedited approval.